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Summary. Eight normal subjects (3 females and 5 males) 
were studied using intravenous L-[ lie] deprenyl and posi- 
tron emission tomography. In a single blind study one sub- 
ject received tracer alone, one subject received an oral 
pre-dose of 20 mg of L-deprenyl and 6 subjects received 
oral pre-doses of 10 to 50 mg of a novel reversible MAO-B 
inhibitor (Ro 19-6327). Dynamic PET scans beginning 
12 h after the oral dose were collected over 90 rain and ar- 
terial blood was continuously sampled, Data analysis was 
modelled for two tissue compartments and using an itera- 
tive curve fitting technique the value of the rate constant 
for irreversible binding of L-[~IC] deprenyl to MAO-B 
(k3) in whole brain was obtained for each subject. 
The dose response curves obtained indicated that a 
dose of at least 0.48 mg. kg- ~ of Ro 19-6327 was necessary 
for > 90% decrease in whole brain k3. Inhibition of 
MAO-B in platelets isolated from blood samples taken at 
the time of scanning correlated strongly with decrease in 
whole brain k3 (r = 0.949). 
The results indicate that PET can be used to determine 
the dose of Ro 19-6327 necessary to inhibit > 90% of brain 
MAO-B. This technique is an attractive alternative to 
traditional large scale patient-based dose-finding studies, 
Moreover it is shown that inhibition of platelet MAO-B 
can be used as a marker for central MAO-B inhibition 
with Ro 19-6327. 
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The MPTP model of Parkinson's Disease (PD) suggests 
that monoamine oxidase may elaborate nvironmental 
toxins and, with free radical formation, may play a central 
role in the oxidative mechanisms which perhaps predis- 
pose to nigro-striatal degeneration [1]. L-deprenyl has 
been used to treat patients with PD [2] and was recently 
shown to slow disease progression [3]. The preliminary re- 
sults of a major trial confirm that 10 mg/day delays the 
onset of disability requiring L-Dopa medication associ- 
ated with early and untreated PD [4]. Ro 19-6327 (N-(2- 
aminoethyl)-5-chloro-2-pyridine carboxamide HC1) is a 
reversible, highly selective inhibitor of MAO-B [5]. It is a 
substrate for MAO-B on human platelet and brain mem- 
branes and is thought o be converted by oxidative deami- 
nation to an intermediate which then inhibits reversibly 
the MAO-B on its active site [6]. Due to its potent inhibi- 
tion of MAO-B, Ro 19-6327 prevents (in mice) the neuro- 
toxicity caused by 1-Methyl-4-Phenyl-l,2,3,6,tetrahydro- 
pyridine (MPTP) [7]. 
In this study, rather than using a time consuming and 
expensive dose-finding study in parallel groups of pa- 
tients, PET has been used to determine the minimum dose 
of Ro 19-6327 necessary to inhibit > 90% of brain MAO-  
B in normal subjects prior to clinical trials in phase II of 
development. 
Subj ects and methods 
Subjects 
Eight healthy volunteers between the ages of 55 and 71 were studied. 
Health was assessed by medical history, full clinical examination, 
haematological nd biochemical profile and urinalysis. Older sub- 
jects were specifically chosen as being representative of the target 
population of Parkinsonian patients and in view of the known in- 
crease with age of brain MAO-B content. Demographic details of 
the subjects are shown in Table 1. All subjects gave informed written 
consent and local ethics committee approval was granted. 
Study protocol 
Six subjects received asingle oral dose of between 10 and 50 mg of 
Ro 19-6327 and one subject received asingle oral dose of 20 mg L- 
deprenyl (selegiline) 12 h before PET scanning (Table 1). 
Previous studies had shown complete inhibition of platelet 
MAO-B by only 5 mg of Ro 19-6327, the duration of maximum in- 
hibition being dose dependent [8], and were a guide to the likely re- 
quired dose for inhibition of brain MAO-B. PET scans were per- 
formed on the CT1931/08/12 (CTI Inc., Knoxville, Tennessee, USA) 
scanner at the MRC Cyclotron Unit. The performance of this scan- 
ner has been described elsewhere [9]. 
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Table 1. Details of the 8 subjects tudied 
Subject Age Sex Weight Dose of Dose of 
no. (kg) Ro 19-6327 Ro 19-6327 
(rag) (mg/kg) 
1. 59 M 74 0 0.00 
2. 55 M 88 10 0.11 
3. 70 M 85 20 0.24 
4. 71 F 55 15 0.27 
5. 67 F 62 25 0.41 
6. 63 F 53 25 0.48 
7. 55 M 73 50 0.69 
8. 70 M 88 L-Deprenylpre-dose (20mg) 
Subjects were positioned in the scanner with the orbito-meatal 
line parallel to the detectors. An individual moulded expanded poly- 
styrene head support was used in each case. A 22 G cannula was in- 
serted into the radial artery after establishing patent collateral circu- 
lation and after subcutaneous infiltration with 1% bupivacaine 
(Marcain). A 10 rain transmission scan for attenuation correction 
was collected using a retractable 68Ga/6SGe ring source. All 8 subjects 
received bolus intravenous injections of saline solutions of L-[tlC] 
deprenyl (mean = 8.23 mCi, SD = 3.06) at the start of the scan. L- 
[~1C] deprenyl was prepared by alkylation of the N-demethyl com- 
pound with IzC methyl iodide. Specific radioactivities were 70 to 
340 mCi- gmo1-1 and weights of drug injected were 6.2 to 17.1 gg. Dy- 
namic scans were collected from the time of injection and for a peri- 
od of 90 minutes, divided into 48 time frames. Frame length was in- 
creased from 5 s initially to 10 rain at the end of the study. 
Blood was continuously sampled from the arterial cannula at 
5 ml.min -1 for at least 10 min but was stopped at this point in the 3 
lighter subjects. In the remaining subjects ampling continued up to 
90 rain at 2.5 ml. rain- 2. The system used for continuous selective de- 
tection of positrons in blood has been described before [101. Samples 
were taken at 5, 10, 15 and 20 rain for L-[IlC] deprenyl metabolite 
analysis. Calibration samples were taken for whole blood and plas- 
ma activity at regular intervals between 5 and 90 min. Samples for 
plasma levels of Ro 19-6327 and for the estimation of platelet MAO- 
B activity were taken at .5, 1, 2, 3, 4, 6, 8, 123/4 and 24 h post oral 
predose. Platelet MAO-B activity was measured radiochemically. 
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absorbance (254 nm) and radioactivity using a sensitive NaI detec- 
tor. The eluate from the HPLC column was collected (0.5 ml frac- 
tions) using a fraction collector and fractions counted on a Gamma 
counter (LKB Pharmacia). The radioactivity in fractions collected 
for a given HPLC injection was plotted as a function of time and the 
ratio of unchanged L-[~C] deprenyl to [11C] metabolites thus deter- 
mined. This data was then used to determine the percentage of total 
activity represented by L-[~C] deprenyl in plasma at a given time 
point. 
Estimation of platelet MA O-B activity 
A 10 ml venous blood sample was collected via an 18 G cannula in a 
10 ml plastic syringe containing l ml of an EDTA solution (1% in 
saline). After gentle shaking the blood sample was transferred to a 
polystyrene tube and centrifuged at room temperature for 15 rain at 
200 xg. The resulting platelet rich plasma (PRP) was transferred to a 
polyethylene tube using a plastic pipette, avoiding carry-over of ery- 
throcytes. The PRP sample was then centrifuged for 10 min at 
3000 xg at 4 °C. The remaining pellet was washed in the polyethylene 
tube with 2 ml of ice-cold modified Tyrode. The washed pellets were 
sedimented by centrifugation and the washing procedure repeated 
for a second time. The supernatant was discarded and the platelet 
pellets tored a t -  20 °C until MAO-B activity was assayed. 
For the MAO-B assay the platelet pellet was suspended in300 gl 
saline and was lysed by addition of 2.7 ml 0.1 M potassium phos- 
phate buffer, pH 7.4 and vigorous vortexing. MAO-B activity was 
determined by adding to 15 ml glass tubes the following incubation 
mixture: 50 ~tl platelet lysate, 200 gl potassium phosphate buffer 
0.5 M, pH 7.4, 0.5 g114C-2-phenylethylamine (14C-PEA, Amersham 
UK, 60 Ci. retool- i) and 49.5 gl unlabelled PEA to yield a final PEA 
concentration of0.02 mmo1.1 x. After incubation of this mixture for 
10 rain at 37 °C under continuous haking, the reaction was stopped 
by the addition of 200 gl 2N HC1. The deaminated products were ex- 
tracted into 5 ml n-heptane by vigorous haking for 10 rain at room 
temperature. After low speed centrifugation, the aqueous bottom 
phase was frozen in dry ice/petrolether, and the organic phase 
poured into counting vials. After addition of 5 ml of Bio-Fluor 
(NEN) the radioactivity was counted by liquid scintillation spectro- 
metry (counting efficiency 90-92%). 
Metabolite analysis 
The analytical procedure described is a modification of a method 
originally reported for [tiC] Carfentanil [11]. Arterial blood samples 
(15 ml) were taken at 5, 10, 15 and 20 rain in heparinised syringes 
after L-[I~C] deprenyl injection. Cell free plasma was obtained by 
centrifugation and processed using a solid phase extraction proce- 
dure before HPLC analysis. 
Two C18 Sep-Pak cartridges (Waters Associates) in series were 
activated using methanol (5 ml) and further washed with ammonium 
formate solution (10 ml, 0.1 M). Cell free plasma (5 ml) spiked with 
cold L-deprenyl (200 ~,g) as carrier was passed slowly through the 
Sep-Paks which were subsequently washed with ammonium formate 
solution (50 ml, 0.1 M) to remove residual proteins. In control ex- 
periments where whole blood was spiked with L-[lzC] deprenyl 
(100 gCi) and cold L-deprenyl (1 rag), greater than 98% of the total 
plasma radioactivity was retained on the Sep-Paks. 
The l~C-activity retained on the Sep-Paks was eluted using meth- 
anol (4 ml). More than 95% of the radioactivity was removed from 
the Sep-Paks using this procedure. Ammonium formate (0.1 M) was 
then added to the methanol eluate in order to adjust he composition 
to that of the HPLC mobile phase. One ml of this solution was then 
injected onto a reverse phase HPLC column ("p-Bondapak", par- 
ticle size 10 pro, 30 cm x 3.9 mm internal diameter, Waters Associ- 
ates) eluted at 3.0 ml-min -1 with a mixture of methanol and am- 
monium formate (0.1 M) [65: 35]. The eluent was monitored for UV 
Image analysis and modelling of data 
The L-[11C] deprenyl scans were analysed using image analysis oft- 
ware (Analyze version 2.0, Biodynamics Research Unit, Mayo 
Foundation, USA) on Sun 3/60 Workstations. The details of the 
quantitative analysis will be described elsewhere. Whole brain re- 
gions of interest were identified for each scan on 15 planes. Average 
values of activity for each of these regions were calculated. Time ac- 
tivity curves were plotted for each subject and the data were ana- 
lysed using the arterial plasma curve, corrected for metabolites and 
dispersion, as the indicator of the input function to the tissue. The 
plasma to whole blood ratio time course obtained from the calibra- 
tion samples was fitted to a multiexponential function. This function 
was in turn used to transform the whole blood time activity curve 
into a plasma curve. Subsequently the level of metabolites obtained 
from the metabolite samples was fitted to a single exponential. This 
function was used to extract he true input function of unchanged L- 
[~C] deprenyl from the plasma curve. 
The kinetics of brain L-[~IC] deprenyl were modelled using the 3 
compartments shown in Fig.1. The model consists of a vascular 
(plasma) compartment and two tissue compartments hat corre- 
spond to (a) free and non-specifically bound tracer and (b) enzyme 
bound tracer. Three rate constants were used to describe tracer up- 
take. K1 and k2 are the constants for transport in and out of the tissue 
space respectively, and k3 is the constant for binding to the MAO-B. 
The rate constant k3 for an irreversible inhibitor, if accurately 
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Compartment 1 Compamnent 2 Compartment 3 
Fig. 1. Schematic representation f the 3-compartment model. The 
constants kl,  k2 and k3 are the first order rate constants for transport 
of tracer among the compartments 
measured, gives an index of enzyme concentration because k3 = ka 
x available binding sites, with ka (the association rate constant of li- 
gand binding to enzyme) assumed to be invariant at trace concentra- 
tions. Thus k3 is a more direct estimate of MAOB binding than other 
methods of analysis especially those which include a blood flow com- 
ponent and may therefore be confounded in studies of drugs that af- 
fect perfusion. Binding of L-[zlC] deprenyl is essentially irreversible 
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Fig.2. Time activity curves for whole brain (circles) and metabolite 
corrected plasma (solid) following injection of L-[~C] deprenyl 
without predosing (subject 1) 
Results 
For all doses of Ro 19-6327 there was virtually 100% in- 
hibition of platelet MAO-B up to 4 h post-dose. After this 
time there was a dose related recovery of MAO-B activity, 
which for the high doses was not completely normalised at 
24 h post-dose, when the final sample was taken. At 123/4 h 
after drug ingestion the effective dose for 50% inhibition 
(EDs0) was between 0.11 and 0.27 mg. kg- ~ (Table 2). 
Following injection of the L-[~xC] deprenyl, radioac- 
tivity rapidly entered the brain. In the subject who re- 
ceived no pre-treatment, activity remained at a high level 
throughout he study due to the irreversible nature of the 
tracer-enzyme interaction (Fig.2). Plasma clearance of 
total radioactivity was rapid (Fig. 2). The amount of un- 
changed tracer in plasma declined to 26% in the first 
15 min as determined by HPLC. In the subjects pre-dosed 
with either unlabelled 1-deprenyl or > 0.41mg.kg -~ of 
Ro 19-6327 there was total washout of the tracer from 
brain, reflecting extensive central enzyme blockade. In- 
itial extraction of the tracer was not affected by the pre- 
dose (Fig. 3). 
Values of k3 showed a steep decrease with increasing 
dose of Ro 19-6327 and the highest dose given was as ef- 
Table 2. Platelet MAO-B activity and % inhibition for the eight sub- 
jects 
Dose of Platelet MAO-B Platelet MAO-B % Platelet 
Ro 19-6327 activity pre-dose activity at time of MAO-B 
(mg- kg- 1) (nmol- h- 1. scan (nmol. h t. inhibition at 
mg tprot.) mg lprot.) time of scan. 
0.00 14.4 13.0 09.3 
0.11 ~ 13.6 8.88 34.6 
0.24 14.0 6.62 52.8 
0.27 20.6 8.07 60.8 
0.41 17.4 2.87 83.9 
0.48 b 24.9 4.03 83 5 
0.69 26.8 2.67 90.1 
Depreny120 mg 16.6 0.03 99.8 
a data limited by interrupted blood sampling 
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Fig.3. Time activity curves for whole brain (circles) and mctabolite 
corrected plasma (solid) following injection of L-[uC] deprenyl with 
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Fig.4. Whole brain dose response curve (100*k3/k3 [tracer alone}) 
vs dose of Ro 19-6327 (mg/kg) 
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Table 3. Values of k3 and decrease ink3 expressed asa percentage of 
tracer alone k3 for the eight subjects 
Dose of k3 for whole decrease 
Ro 19-6327 brain ROI in brain k3. 
(rag. kg- 1) (rain -i) (% tracer alone) 
0.00 0.344 00.0 
0.11" 0.353 - 02.62 
0.24 0.152 55.8 
0.27 0.198 42.4 
0.41 0.051 85.2 
0.48 b 0.017 95.1 
0.69 0.028 91.9 
Depreny120 mg 0.030 91.3 
a data limited by interrupted blood sampling 
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Fig.5. % Platelet MAO-B inhibition vs % decrease brain k3. The 2 







Fig.& PET images from comparative slices for each subject with 
brain activity normalised for integrated plasma ctivity. The images 
are summated from the dynamic scans collected between 10 and 
90 rain after injection of L-[~IC] deprenyl 
fective a blocker as unlabelled L-deprenyl (Fig. 4). A dose 
of 0.48 mg. kg- 1 of Ro 19-6327 produced at least 90% de- 
crease in brain k3 (Table 3). Fig. 5 shows the correlation of 
% decrease in brain k3 for L-[1aC] deprenyl in the 
presence of Ro 19-6327 with platelet MAO-B inhibition 
determined at the scan time. The correlation coefficient is
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0.949. Fig. 6 shows PET images from comparative slices 
for each subject with brain activity normalised for inte- 
grated plasma activity. 
Discussion and conclusions 
In vivo studies of monoamine oxidase in man have been 
made possible by the development of irreversible 
"suicide" inhibitors of MAO which inhibit selectively only 
one type of MAO when administered in low doses. Clor- 
gyline and L-deprenyl are inhibitors of MAO-A and 
MAO-B respectively and can be labelled at the N-methyl 
position with UCarbon, a nuclide which decays by positron 
emission with a half life of 20.4 minutes. PET studies using 
these z lC tracers have shown an anatomical distribution of 
activity which parallels the distribution of MAO in auto- 
psy material [13]. PET has also been used to measure 
functional MAO activity in man and to measure turnover 
rates in primates [13, 14]. The use and dose response 
profile of MAO-B inhibitors is under close scrutiny in Par- 
kinson's Disease, with particular interest in highly selec- 
tive, reversible inhibitors uch as Ro 19-6327 which does 
not show the tyramine pressor effect seen with higher 
doses of less selective irreversible inhibitors [15]. 
Prior to the development ofquantitative imaging tech- 
niques, in vivo assessment ofcertain drug responses in the 
CNS such as enzyme inhibition or receptor occupancy re- 
lied heavily on analogy with simpler tissues. Of the periph- 
eral "models" of the CNS platelets have been one of the 
most frequently and extensively investigated. The finding 
that Ro 19-6327 inhibits platelet MAO-B in humans indi- 
cates that the drug is an MAO-B inhibitor in man. In isola- 
tion, this information says nothing about whether the drug 
crosses the blood brain barrier or what doses are required 
to obtain maximal inhibition in the brain. Attempts to di- 
rectly correlate platelet MAO-B activity with activity in 
normal brain material obtained either post-mortem [16] 
or during neurosurgery [17] have failed. We have per- 
formed platelet sampling in conjunction with PET meas- 
urements to test the validity of using platelet MAO-B as- 
says as a model for brain MAO-B activity. 
Using PET we have confirmed that Ro 19-6327 
crosses the blood-brain barrier and causes dose depend- 
ent inhibition of brain MAO-B. We have also shown that 
inhibition of the peripheral platelet MAO-B by Ro 19- 
6327 can be considered a good model for monitoring brain 
MAO-B inhibition by this drug. The increasing interest in 
the use of MAO inhibitors in the treatment of Parkinson's 
Disease (PD), Senile Dementia of the Alzheimer Type 
and Depressive Illness indicates the need for accurate 
determination i  vivo of brain MAO activity, 
Efficacy of an MAO-B inhibitor in the prevention of 
progression of PD can only reasonably be judged after one 
year of treatment and with large numbers of patients per 
treatment group. On theoretical grounds, the hypothesis 
in PD which implicates monoamine oxidase type B in the 
neurodegenerative m chanism would suggest hat the 
more MAO-B is inhibited by a drug, the greater the pro- 
tective effect. Therefore, a traditional dose-finding study 
would require parkinsonian patients to be given the hig- 
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hest tolerated ose of Ro  19-6327 for one year with the at- 
tendant risks of inducing side effects within this time. The 
present study shows how PET  may be used, possibly as an 
alternative to time consuming and expensive dose-finding 
studies in parallel groups of patients, to determine the 
dose of a MAO-B  inhibitor, in this case Ro  19-6327, 
necessary to inhibit > 90% of brain MAO-B .  
This technique could be extended to other therapeutic 
areas. For example, in the case of the benzodiazepines it is 
unknown how much receptor occupancy is needed to ob- 
tain an anxiolytic effect in humans. However, for each of 
the benzodiazepines on the market the anxiolytic dose is 
known. Using PET  and ~lC-flumazenil t could be seen 
whether four or five different benzodiazepines produce 
equivalent receptor occupancy at anxiolytic doses. A new 
compound could then be rapidly tested for the dose which 
gives an "anxiolytic" receptor occupancy. A similar strate- 
gy could be used for specific monoamine oxidase type A 
inhibitors, which are being developed as antidepressive 
drugs, using llC-clorgyline as the PET  tracer. The early 
clinical development of new drugs may therefore soon in- 
clude, as a matter of course, measures of clinical efficacy in 
combination with pharmacodynamic studies using PET  
and suitable tracers to confirm the test drug's penetrat ion 
of the blood brain barrier and allow accurate quantitation 
of its action on central enzyme or receptor systems. 
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